NCCN Meeting on Blood Cancers Will Be Virtual for the First Time

NCCN has announced this year's NCCN Annual Congress: Hematologic Malignancies will be fully online and open to all attendees at no cost. This annual gathering provides instruction from world-renowned experts for determining the best emerging techniques and practices for various blood cancers, including leukemia, lymphoma, and multiple myeloma. The virtual event will provide numerous opportunities for physicians, nurses, pharmacists, and other health professionals to earn continuing education credits, interact with experts, and network with peers.

The NCCN Virtual Annual Congress: Hematologic Malignancies will take place on October 9–10, 2020, with the corresponding NCCN Virtual Nursing Forum taking place on October 8, 2020.

The programs will include diagnostic and therapeutic advances, NCCN Guidelines updates, controversies in treatment, and currently salient topics such as: Navigating the Jargon of Molecular Testing, Implications of Biology on Treatment, Considering CAR T for All, Optimizing Outpatient Care, and Managing Cardiac Complications. The complete agenda can be viewed at [NCCN.org/hem](https://www.nccn.org/hem).

"The rapid pace of change in cancer care can pose challenges for clinicians trying to stay up-to-date on how to optimize patient outcomes," said event co-chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. "We're eager to reduce any knowledge and practice gaps by sharing information on the therapeutic advances that help us individualize treatment selection, minimize toxicities, and manage adverse events."

"The NCCN Annual Congress for Hematologic Malignancies offers expert analysis of the latest clinical trial data," said co-chair Ranjana H. Advani, MD, Stanford Cancer Institute. "Patients benefit when providers are well equipped to utilize cutting-edge guidelines. These comprehensive presentations, case studies, and interactive discussions will allow clinicians to stay abreast of advances in the evolving diagnostic and treatment landscape."

The virtual format for the congress will provide opportunities for participants to engage with faculty in real-time and also include an online exhibit hall and breakout rooms for networking with colleagues.

"Our new platform allows us to make vital cancer information more accessible than ever, as we adjust for the ongoing COVID-19 pandemic," explained Robert W. Carlson, MD, Chief Executive Officer, NCCN. "We look forward to having attendees from around the world and throughout the oncology ecosystem join us from the convenience of their home or office without the need for travel."

Anyone who is not able to join the interactive sessions in real-time will have an opportunity to view recordings from the webcasts from November 1, 2020, through October 31, 2021, at education.nccn.org. A related Case of the Week series will also launch after the Congress. Join the conversation online with the hashtag #NCCNhem20.

NCCN Oncology Research Program, with Taiho Oncology, to Explore New Research into Oral Medication Targeting Tumor Suppression Genes

The NCCN Oncology Research Program (ORP) recently announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the

Cont. on page xlix.

“

The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies will provide the latest evidence and expert consensus, online October 8–10.

“

Studies will assess safety and effectiveness of an oral combination of decitabine and cedazuridine.

doi: 10.6004/jnccn.2020.0051

efficacy of decitabine and cedazuridine. This novel, fixed dose combination of the hypomethylating agent decitabine, combined with the cytidine deaminase inhibitor cedazuridine permits effective oral administration of decitabine by preventing degradation in the gut and liver. Studies will investigate decitabine and cedazuridine in hematologic malignancies. Research funding will be provided by a \$2 million grant from Taiho Oncology.

"Patients and advocates frequently express preference for oral medications over intravenous infusions," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "By learning more about how patients with various cancer types respond to this kind of treatment when it's delivered in an oral dosage form, we have the potential to make great strides in improving comfort, convenience, treatment adherence, and hopefully cure rates."

"NCCN's research on decitabine and cedazuridine tablets can provide important insights regarding oral treatment options for patients with hematologic malignancies that can be taken from their home," said Martin J. Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. "We thank NCCN for expanding the generation of clinical data for decitabine and cedazuridine in patients with hematologic malignancies. This research is significant as both patients and healthcare providers look to reduce the number of in-office visits required for intravenous administration of their treatment during the current global pandemic."

The specific tumor types to be targeted for study will be determined by a group of cancer research specialists from NCCN Member Institutions who form the Request for Proposals (RFP) Development Team. The RFP will be shared in the coming months, with an announcement of selected projects to follow.

The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.

Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish

NCCN has announced the availability of multiple non-English language versions of NCCN Guidelines for several high-incidence cancer types. Expert recommendations in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines App.

NCCN is devoted to defining and advancing high-quality, high-value, patient-centered cancer care globally. NCCN Guidelines are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently updated clinical practice guidelines available in any area of medicine. They are written by subject-specific,

Cont. from page xlvii.

“
Gold standard clinical practice guidelines in oncology translated for greater global accessibility; free online at NCCN.org/global.

multidisciplinary panels of experts from across 30 leading cancer centers in the United States.

"NCCN is committed to maintaining and growing a library of global resources to ensure that providers and patients have access to the most up-to-date standards in cancer care around the world," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "Nearly half of our registered users live outside the United States and many may be more comfortable in languages other than English; NCCN Guidelines have been downloaded in more than 180 countries. Expanding the number of non-English translations increases the accessibility of this crucial information throughout Europe and other parts of the world."

The recently translated NCCN Guidelines cover the following cancer types:

- Acute Myeloid Leukemia (AML) — Portuguese and Spanish
- B-Cell Lymphomas — French, German, Italian, and Spanish
- Breast Cancer — Spanish
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — Portuguese and Spanish
- Colon Cancer — Spanish
- Gastric Cancer — Spanish
- Hairy Cell Leukemia — Italian and Spanish
- Head and Neck Cancers — Spanish
- Hodgkin Lymphoma — Italian and Spanish
- Melanoma (Cutaneous) — Spanish
- Multiple Myeloma — Portuguese and Spanish
- Non-Small Cell Lung Cancer — Italian and Spanish
- Primary Cutaneous Lymphomas — Italian and Spanish
- T-Cell Lymphomas — Italian and Spanish

NCCN also offers supportive care guidelines, including the Russian language version of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities, that covers immunotherapy-related adverse events (irAEs) from immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. The NCCN Distress Thermometer—a tool for gauging and addressing the psycho-social wellbeing in people with cancer—has also been translated into 46 languages, including French, German, Italian, Portuguese, Russian, and Spanish.

In addition to all of these recommendations for adults with cancer, NCCN has also recently announced the translation of NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia into Portuguese and Spanish.

Visit [NCCN.org/global/international_adaptations.aspx](https://www.nccn.org/global/international_adaptations.aspx) to view and download 24 global adaptations and 230 translations of NCCN resources across 47 different languages. The NCCN global team also offers patient-friendly versions in several languages, including Czech, French, German, Italian, Russian, and Spanish. NCCN provides NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework) and NCCN Harmonized Guidelines that merge optimal recommendations and pragmatic considerations for treatment in resource-constrained settings, such as low- and middle-income countries.

Learn more at [NCCN.org/global](https://www.nccn.org/global) and join the conversation online with the hashtag #NCCNGlobal.

Up-to-Date Leading Cancer Treatment Recommendations From NCCN Now Available in Chinese

NCCN has announced the availability of both new and updated Chinese language versions of NCCN Guidelines for numerous high-incidence cancer types. These treatment recommendations can be accessed for free at [NCCN.org/global](https://www.nccn.org/global) or via the Virtual Library of NCCN Guidelines App.

NCCN is devoted to defining and advancing high-quality, high-value, patient-centered cancer care globally. There are currently 24 global adaptations and 230 translations of NCCN resources across 47 different languages.

"Publishing NCCN Guidelines in multiple languages helps us ensure people everywhere can have access to the best cancer care at the right time," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "Cancer treatment methods are becoming more sophisticated and complicated every day, thanks to emerging research. These new and updated Chinese-language guidelines enhance understanding for primarily Chinese-fluent oncology providers in Asia and throughout the world, and allow them to readily stay up-to-date on the latest evidence-based and expert consensus recommendations."

China is home to the largest number of downloads for NCCN Guidelines outside the United States, with more than 200,000 downloads in 2019 alone. The country also boasts the highest number of non-US verified users for [NCCN.org](https://www.nccn.org) with more than 42,000. South Korea, Japan, and Thailand are also among the most-represented countries to download NCCN Guidelines.

Chinese-language NCCN Guidelines currently cover the following topics:

- Acute Myeloid Leukemia (AML)
- Breast Cancer
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Colon Cancer
- Gastric Cancer
- Hairy Cell Leukemia
- Head and Neck Cancers
- Hodgkin Lymphoma
- Melanoma (Cutaneous)
- Multiple Myeloma
- Non-Small Cell Lung Cancer
- Primary Cutaneous Lymphomas
- T-Cell Lymphomas

NCCN has also recently announced the translation of NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia into Japanese and Chinese. The NCCN Distress Thermometer—a tool for gauging and treating the psycho-social wellbeing in people with cancer—has also been translated into 46 languages, including Chinese, Japanese, Korean, Malay, Thai, and many more. Visit [NCCN.org/global/international_adaptations.aspx](https://www.nccn.org/global/international_adaptations.aspx) to view and download these free resources.

The NCCN global team also offers patient-friendly versions in several languages, including Chinese, Japanese, and Korean. Learn more at [NCCN.org/global](https://www.nccn.org/global) and join the conversation online with the hashtag #NCCNGlobal.

“

NCCN has announced the availability of both new and updated Chinese language versions of NCCN Guidelines for numerous high-incidence cancer types.